Dr. Nirali N. Shah
Claim this profileNational Institutes of Health, Clinical Center
Studies Leukemia
Studies Acute Myeloid Leukemia
9 reported clinical trials
12 drugs studied
Area of expertise
1Leukemia
CD33 positive
Philadelphia chromosome positive
CD22 positive
2Acute Myeloid Leukemia
CD33 positive
CD123 positive
Affiliated Hospitals
Clinical Trials Nirali N. Shah is currently running
Inotuzumab Ozogamicin
for Leukemia and Lymphoma
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Recruiting1 award Phase 210 criteria
Stem Cell Transplant + Mylotarg
for Acute Myeloid Leukemia
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Recruiting1 award Phase 1 & 26 criteria
More about Nirali N. Shah
Clinical Trial Related7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Nirali N. Shah has experience with
- VOR33
- CD33CART
- Mylotarg
- CRG-022
- VCAR33
- Inotuzumab Ozogamicin
Breakdown of trials Nirali N. Shah has run
Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nirali N. Shah specialize in?
Nirali N. Shah focuses on Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Leukemia has involved CD33 positive patients, or patients who are Philadelphia chromosome positive.
Is Nirali N. Shah currently recruiting for clinical trials?
Yes, Nirali N. Shah is currently recruiting for 6 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Nirali N. Shah has studied deeply?
Yes, Nirali N. Shah has studied treatments such as VOR33, CD33CART, Mylotarg.
What is the best way to schedule an appointment with Nirali N. Shah?
Apply for one of the trials that Nirali N. Shah is conducting.
What is the office address of Nirali N. Shah?
The office of Nirali N. Shah is located at: National Institutes of Health, Clinical Center, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Institutes of Health, Clinical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.